Table 4 Treatment regimens main results of all included studies
Study | Surgery | Chemotherapy | Beam-Delivery | Total dose (Gy RBE) | Fractions (n) | Dose/fraction Gy (RBE) |
|---|---|---|---|---|---|---|
Shiba 2021 [10] | 7 (13.2%) | 6 (11.3%) Osteosarcoma only | NR | 64–70.4 | 16 | 4.0–4.4 |
Mohamad 2018 [11] | 4 (15%) | 26 (100%) | Passive scanning | 52.8–73.6 | 16 | 3.3–4.6 |
Imai 2017 [12] | 0 | 0 | Passive scanning | 64–73.6 | 16 | 4.0–4.6 |
Imai 2016 [13] | 0 | 0 | Passive scanning | 64–73.6 | 16 | 4.0–4.6 |
Matsunobu 2012 [14] | 11 (14.1%) | 61 (78.2%) | Passive scanning | 52.8–73.6 | 16 | 3.3–4.6 |
Imai 2011 [15] | 11 (11.6%) | 0 | Passive scanning | 52.8–73.6 | 16 | 3.3–4.6 |
Mizoe 2009 [16] | 33 (100%) | 0 | Passive scanning | 48.0–60.8 | 16 | 3.0–3.8 |
Mattke 2018 [17] | 75 (94.9%) | 0 | Active scanning | 60 | 20 | 3.0 |
Uhl 2014 [18] | 139 (89.7%) | 0 | Active scanning | 60 | 20 | 3.0 |
Uhl 2014 [19] | 67 (84.8%) | 0 | Active scanning | 60 | 20 | 3.0 |
Combs 2009 [20] | 0 | 0 | Active scanning | 60 | 20 | 3.0 |
Wu 2019 [21] | 0 | NR | Active scanning | 69 (57–80) | 18–25 | 3.2 |